About Alexza
Alexza is a company based in Mountain View (United States) founded in 2000. Alexza has raised $97 million across 8 funding rounds from investors including T. Rowe Price, Frazier Healthcare Partners and Abingworth. Alexza offers products and services including Staccato Technology and Adasuve. Alexza operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, MannKind Corp, Neurocrine and PTC Therapeutics, among others.
- Headquarter Mountain View, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alexza Pharmaceuticals
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$97 M (USD)
in 8 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Feb 24, 2016
-
Investors
T. Rowe Price
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alexza
Alexza offers a comprehensive portfolio of products and services, including Staccato Technology and Adasuve.
Handheld inhaler for rapid systemic drug delivery to treat medical conditions.
Treatment for agitation in schizophrenia or bipolar disorder via inhalation.
Funding Insights of Alexza
Alexza has successfully raised a total of $97M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in February 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alexza
Alexza has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include T. Rowe Price, Frazier Healthcare Partners and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in the US
|
Locked | Locked | Locked | |
|
Investments are made in life sciences firms across all stages.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Alexza
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alexza
Investment portfolio details for Alexza
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alexza
Detailed financials for Alexza
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alexza Comparisons
Peer comparison for Alexza
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alexza
Alexza operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, MannKind Corp, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Alexza
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alexza
Complete news archive for Alexza
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alexza
Alexza was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Alexza is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Alexza is a funded company, having raised a total of $97M across 8 funding rounds to date.
Founded in 2000, Alexza is engaged in the biotechnology sector, focusing on the development of inhalation-based therapeutics for acute and intermittent conditions. Proprietary Staccato system technology is utilized to vaporize drug compounds for delivery through deep lung inhalation. Key products include treatments for migraine, panic attacks, breakthrough pain, and acute agitation in schizophrenia patients. Operations are based in Mountain View, United States.
Alexza's top competitors include Jazz Pharmaceuticals, MannKind Corp and PTC Therapeutics.
Alexza offers Staccato Technology and Adasuve.
Alexza has 14 investors. Key investors include T. Rowe Price, Frazier Healthcare Partners, Abingworth, Burrill and Company, and Alloy Ventures.